Biocon Ltd Achieves Groundbreaking Milestones in FY25, Expanding Access to Affordable Diabetes Care and Strengthening Biosimilars Presence

Biocon Ltd, a leading biopharmaceutical company, reported steady growth in FY25 with a 5% increase in revenue and EBITDA profit. The company made strategic capital investments to expand manufacturing capacity, enhance R&D capabilities, and strengthen global supply chain infrastructure. Biocon's Biosimilars business led the performance with a 15% growth, while the Generics and Research Services businesses grew by 8% and 4%, respectively. The company made a significant foray into the 'diabesity' therapeutic area with the UK launch of generic Liraglutide, marking a unique position in diabetes care. Biocon also strengthened its presence in the U.S. market with the launch of its fifth biosimilar, Yesintek, and secured EU approvals for Semaglutide and Tirzepatide. The company is well-positioned to tap into the projected USD 144 billion GLP-1 market by 2029.